Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment

NCT ID: NCT05109377

Last Updated: 2021-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-24

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators analyze the patients' endocan levels, IIEF scores, and hormon levels both before and after tadalafil (5 or 20mg) treatment. The investigators want to see erectile dysfunction severity and tadalafil treatment relations with endocen level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will include at least 90 patients in study. Blood tests will taken before and after tadalafil treatment and will store at -80 celcius degree.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Endocan Erectile dysfunction Tadalafil

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

5mg tadalafil

5mg tadalafil

Group Type OTHER

Endocan

Intervention Type DIAGNOSTIC_TEST

Endocan will measured before and after treatment

tadalafil

Intervention Type DRUG

tadalafil

20mg tadalafil

20 mg tadalafil

Group Type OTHER

Endocan

Intervention Type DIAGNOSTIC_TEST

Endocan will measured before and after treatment

tadalafil

Intervention Type DRUG

tadalafil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endocan

Endocan will measured before and after treatment

Intervention Type DIAGNOSTIC_TEST

tadalafil

tadalafil

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Patients with erectile dysfuction

Exclusion Criteria

* Psychogenic erectile dysfunction
* Erectile dysfunction associated with hormonal disorders
* Drug related erectile dysfunction
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Veysel Bayburtluoğlu

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Veysel Bayburtluoğlu

Role: PRINCIPAL_INVESTIGATOR

Ministry of Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Veysel Bayburtluoğlu

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Veysel Bayburtluoğlu

Role: CONTACT

Phone: +905530299981

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Veysel Bayburtluoğlu

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-93471371-514.10

Identifier Type: -

Identifier Source: org_study_id